HighTide Therapeutics’ HTD1801 Demonstrates Reduced Liver Fat, Improved Glycemic Control and Other Health Measures in Diabetic NASH Patients

-- Phase 2 Data Published Online in Nature Communications -- SHENZHEN, China & ROCKVILLE, Md.--(BUSINESS WIRE)--Phase 2 clinical results with HTD1801, a novel orally active ionic salt of berberine and ursodeoxycholic acid, substantially reduced liver ...

Full "IntellAsia: Resources" article